{"contentid": 488617, "importid": NaN, "name": "Discount checkpoint blocker aims to disrupt market", "introduction": "New York\u00e2\u0080\u0099s Checkpoint Therapeutics has finished enrolling patients in a registration-enabling trial of its experimental checkpoint blocker cosibelimab.", "content": "<p>New York&rsquo;s Checkpoint Therapeutics (Nasdaq: CKPT) has finished enrolling patients in a registration-enabling trial of its experimental checkpoint blocker cosibelimab.</p>\n<p>The trial evaluates the immunotherapy as an option for people with metastatic cutaneous squamous cell carcinoma (cSCC), and has a primary efficacy endpoint of confirmed objective response rate (ORR).</p>\n<p>Checkpoint believes its candidate is a potential best-in-class PD-L1 blocker, with a unique mechanism of action which removes the suppressive effects of PD-L1 on certain anti-tumor components of the immune system.</p>\n<p>If approved, cosibelimab could differentiate itself from currently marketed options by reactivating an antitumor immune response.</p>\n<p>The firm is also hoping to capture market share with a lower-priced alternative to currently available PD-L1s, such as Merck &amp; Co&rsquo;s (NYSE: MRK) Keytruda (pembrolizumab) and Bristol Myers Squibb&rsquo;s (NYSE: BMY) Opdivo (nivolumab), which tend to cost more than $10,000 per month.</p>\n<h2>Registrational trial</h2>\n<p>Top-line results from the study are expected in the fourth quarter of 2021, and the firm plans to submit for regulatory approval in the first half of 2022 if all goes well.</p>\n<p>Checkpoint continues to enroll a registration-enabling cohort of patients with locally advanced cSCC and anticipates that this second indication will also be included in the submissions.</p>\n<p>Based on previously-reported interim data, chief executive James Oliviero said cosibelimab &ldquo;has the potential to be a best-in-class anti-PD-L1 antibody, which we intend to commercialize at a substantially lower price in comparison to currently marketed anti-PD-(L)1 therapies.&rdquo;</p>\n<p>He added: &ldquo;With a compelling safety and efficacy profile, as well as our market disruptive pricing strategy, we believe cosibelimab can achieve meaningful and rapid market share in the $25 billion and growing PD-(L)1 class.&rdquo;</p>", "date": "2021-05-13 11:00:00", "meta_title": NaN, "meta_keywords": "checkpoint, blocker, cosibelimab, trial, market, patients, registration-enabling, Discount, aims, disrupt, Therapeutics, finished, enrolling, experimental", "meta_description": "New York\u00e2\u0080\u0099s Checkpoint Therapeutics has finished enrolling patients in a registration-enabling trial of its experimental checkpoint blocker cosibelimab.", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-05-13 10:45:37", "updated": "2021-05-13 11:02:14", "access": NaN, "url": "https://www.thepharmaletter.com/article/discount-checkpoint-blocker-aims-to-disrupt-market", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "checkpoint_big.jpg", "image2id": "checkpoint_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Immuno-oncology", "topic_tag": "Drug Trial, Research", "geography_tag": "USA", "company_tag": "Checkpoint Therapeutics", "drug_tag": "cosibelimab", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-05-13 11:00:00"}